Structure Therapeutics Inc. cotiza a 23.91 USD y tiene una capitalización bursátil de $1.7B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-lik…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.49 | $-0.35 | $0.20 |
| Estimado | $-0.24 | $-0.38 | $-0.33 | $-0.37 |
| Sorpresa | — | -28.9% | -6.1% | +154.1% |
| Métrica | GPCR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -9.3% | -40.4% | +31.1% |
| ROA | -8.9% | -32.0% | +23.1% |
| Current Ratio | 24.81 | 2.84 | +21.97 |
| Debt / Equity | — | 0.28 | — |